Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection.
about
A new strategy to fight antimicrobial resistance: the revival of old antibioticsA comparison of different antibiotic regimens for the treatment of infective endocarditisAntibiotics for bacteraemia due to Staphylococcus aureusAntibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical woundsCommunity-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicDaptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazoleDose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureusTreatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesisMethicillin-Resistant Staphylococcus aureus Infections.Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs.Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinicOral Antimicrobial Therapy: Efficacy and Safety for Methicillin-Resistant Staphylococcus aureus Infections and Its Impact on the Length of Hospital StayA comparison of clinical features and mortality among methicillin-resistant and methicillin-sensitive strains of Staphylococcus aureus endocarditis.Antimicrobial susceptibility of coagulase-negative staphylococci.MRSA: treating people with infection.Methicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community.Antibiotics and bacterial resistance in the 21st century.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Clinical management of Staphylococcus aureus bacteremia: a review.Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Trimethoprim-sulfamethoxazole for methicillin-resistant Staphylococcus aureus: a forgotten alternative?Methicillin-resistant Staphylococcus aureus in HIV-infected patients.Heterogeneous vancomycin-intermediate susceptibility in a community-associated methicillin-resistant Staphylococcus aureus epidemic clone, in a case of Infective Endocarditis in ArgentinaPharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.Oral antibiotic therapy for the treatment of infective endocarditis: a systematic reviewA review of the current place of glycopeptides in turkish medical practicePredictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycinMethicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections.No Outbreak of Vancomycin and Linezolid Resistance in Staphylococcal Pneumonia over a 10-Year Period.Predictors of mortality in Staphylococcus aureus BacteremiaCommunity-associated methicillin-resistant Staphylococcus aureus: a review.Prospective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistanceStaphylococcal skin infections in children: rational drug therapy recommendations.Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient.Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children.Management of healthcare-associated methicillin-resistant Staphylococcus aureus.Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.Clinical and laboratory features of community-associated methicillin-resistant Staphylococcus aureus: is it really new?
P2860
Q21131083-DAD8F6ED-FD4A-4A0A-BEA9-839888AA7F12Q24185887-710FB3D7-C886-47BF-AA20-02566B70CEAFQ24186950-38AFF69B-4D09-4F4D-AF12-77DA2E5013DCQ24202424-33C1193A-614D-4364-8DA5-1A256E056229Q24614464-F0CEF1BC-6287-456A-B4AA-93C19460CB48Q24620644-C387F19A-84C7-409C-8B2C-5B911499788BQ24631182-E3935C1A-481D-41B0-BDC6-5E95A289DCABQ28368185-35ACA523-C497-4E03-BD99-3D726A518F5DQ30306476-F371C472-17D0-465D-BF34-2EC9D00FE707Q33245188-3018D643-B295-4F1F-B402-2B0D719F8C63Q33264142-3C008C5C-73E4-4355-B810-E48C108B1FE4Q33418076-DBBD3706-B097-46C2-A813-121C2450AEB5Q33628238-3EB0BFB4-0FC1-4DFD-A759-CDBD7E83D18FQ33760227-79734052-1F02-47FB-B357-B91E2A306185Q33850476-6CAB878E-A026-44F7-B093-E8957E321B7EQ33970752-89CE0E9F-37AE-4C87-B9E8-545AD3BCF135Q34156349-D51637F2-4CC3-4C8B-BFF9-96AF8C4AD790Q34157657-2DD54700-3EBD-4EED-AF9F-13FDCA16354AQ34441035-27C26CF2-466B-4580-ABD1-F8BF3CC58057Q34469972-657529A2-B1AF-4662-99D5-AA13EEF1E858Q34478074-61FEB934-F5D3-4C49-8185-D502E8DD03E1Q34979705-10574836-486C-4082-B0BA-B273EA76E70DQ35026548-6ECF5B4D-C503-4192-8F1D-F08E502A32CBQ35035275-82C33BE9-C245-4C9B-850B-9FEA030C4B88Q35116133-6D1CFD92-F25F-4E97-B0A6-68D55CD2E5C0Q35119494-513CC82F-B8ED-4930-A8A6-63F0F16C14FBQ35134138-D1A76917-3C29-4010-9753-7884B20CEADCQ35273507-59D828EA-5158-4F00-ABDE-42D4B0789902Q35376362-35BC1A7E-65CF-4816-8727-B4DA5B2169E8Q35638010-A061ED2B-04DF-42E1-A93C-1C9ABECDC855Q35785093-DE278C04-EEA8-4DD7-BA83-FE32CA3D091BQ35940556-28D4E2F3-4DD2-454A-A62E-6801E78B3E9FQ36070903-2F7EA4DC-4E93-46D6-84F7-068B7D4DFEADQ36086509-C1D5EA11-FD55-4841-8FE6-0367512B12E5Q36116435-EC245936-6530-41A0-9C17-F114F72FA919Q36161246-43331514-A7CA-46E6-B90D-38C4AADA40F1Q36233549-99D4C829-FE2C-4799-9681-6A335635AE84Q36322109-F7A1E355-E937-4543-A0EF-9C82AF1F2950Q36325685-008D2CF1-0CE8-4390-989C-81E21E08EA73Q36390527-4FFF01A1-D0D5-4C02-BCE2-D95B59C2E1B3
P2860
Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Trimethoprim-sulfamethoxazole ...... aphylococcus aureus infection.
@en
Trimethoprim-sulfamethoxazole ...... aphylococcus aureus infection.
@nl
type
label
Trimethoprim-sulfamethoxazole ...... aphylococcus aureus infection.
@en
Trimethoprim-sulfamethoxazole ...... aphylococcus aureus infection.
@nl
prefLabel
Trimethoprim-sulfamethoxazole ...... aphylococcus aureus infection.
@en
Trimethoprim-sulfamethoxazole ...... aphylococcus aureus infection.
@nl
P2093
P1476
Trimethoprim-sulfamethoxazole ...... aphylococcus aureus infection.
@en
P2093
Markowitz N
Saravolatz LD
P304
P356
10.7326/0003-4819-117-5-390
P407
P577
1992-09-01T00:00:00Z